Submitted:
13 June 2023
Posted:
14 June 2023
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and Methods
2.1. Adaptation of the Brazilian questionnaire
2.2. Delphi technique
2.3. Reproducibility
2.4. Study Population
2.4.1. Judge Inclusion Criteria
2.4.2. Patient Inclusion Criteria
2.5. Statistical Analysis
2.6. Factorial Analysis
2.6.1. Exploratory Factor Analysis
2.6.2. Confirmatory Factor Analysis
- Root Mean Square Error of Approximation (RMSEA), where values below 0.08 indicate good model fit [35].
- NCP (estimated non-centrality parameter), a measure used in statistical power analysis for hypothesis testing. It was adjusted with 26 degrees of freedom, and the test of approximate fit considered the null hypothesis RMSEA < 0.05 [36].
- NNFI (non-normed fit index), also known as the Tucker-Lewis Index (TLI), is a goodness-of-fit index used in structural equation modeling (SEM). The NNFI is a relative fit index that compares the fit of a hypothesized model to a baseline model. It is calculated as the difference in the chi-square values of the hypothesized model and the baseline model, divided by the degrees of freedom of the hypothesized model [37]. A NNFI value of 1 indicates perfect fit, while values closer to 0 indicate poorer fit.
- Comparative Fit Index (CFI), where values above 0.95 indicate good model fit [38].
- GFI (goodness of fit index), first proposed by Jöreskog and Sörbom (1981), generally, a GFI value of 0.90 or higher is considered indicative of good fit, although this threshold may vary depending on the specific research context [39].
3. Results
3.1. Adaptation of the questionnaire
3.2. Delphi technique
3.3. Reproducibility
3.4. Factor Analysis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Martin-McGill, K.J.; Jackson, C.F.; Bresnahan, R.; Levy, R.G.; Cooper, P.N. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst. Rev. 2018, 11, CD001903. [Google Scholar] [CrossRef]
- Pong, A.W.; Geary, B.R.; Engelstad, K.M.; Natarajan, A.; Yang, H.; De Vivo, D.C. Glucose transporter type I deficiency syndrome: Epilepsy phenotypes and outcomes. Epilepsia 2012, 53, 1503–1510. [Google Scholar] [CrossRef]
- Kossoff, E.H.; Zupec-Kania, B.A.; Auvin, S.; Ballaban-Gil, K.R.; Christina Bergqvist, A.G.; Blackford, R.; Buchhalter, J.R.; Caraballo, R.H.; Cross, J.H.; Dahlin, M.G.; et al. Practice Committee of the Child Neurology Society Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open 2018, 3, 175–192. [Google Scholar] [CrossRef]
- Veggiotti, P.; De Giorgis, V. Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome. Curr. Treat. Options Neurol. 2014, 16, 291. [Google Scholar] [CrossRef]
- Boison, D. New insights into the mechanisms of the ketogenic diet. Curr. Opin. Neurol. 2017, 30, 187–192. [Google Scholar] [CrossRef] [PubMed]
- Freeman, J.M.; Vining, E.P.G.; Kossoff, E.H.; Pyzik, P.L.; Ye, X.; Goodman, S.N. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia 2009, 50, 322–325. [Google Scholar] [CrossRef] [PubMed]
- Klepper, J.; Leiendecker, B. Glut1 deficiency syndrome and novel ketogenic diets. J. Child Neurol. 2013, 28, 1045–1048. [Google Scholar] [CrossRef] [PubMed]
- Sabate, E. Adherence to Long-Term Therapies: Evidence for Action; World Health Organization: Geneva, Switzerland, 2003. [Google Scholar]
- Jimmy, B.; Jose, J. Patient medication adherence: Measures in daily practice. Oman Med. J. 2011, 26, 155–159. [Google Scholar] [CrossRef] [PubMed]
- Fawcett, J. Thoughts about meanings of compliance, adherence, and concordance. Nurs. Sci. Q. 2020, 33, 358–360. [Google Scholar] [CrossRef] [PubMed]
- Aronson, J.K. Compliance, concordance, adherence. Br. J. Clin. Pharmacol. 2007, 63, 383–384. [Google Scholar] [CrossRef] [PubMed]
- Cramer, J.A.; Roy, A.; Burrell, A.; Fairchild, C.J.; Fuldeore, M.J.; Ollendorf, D.A.; Wong, P.K. Medication compliance and persistence: Terminology and definitions. Value Health 2008, 11, 44–47. [Google Scholar] [CrossRef]
- Ferraris, C.; Guglielmetti, M.; Tamagni, E.; Trentani, C.; De Giorgis, V.; Pasca, L.; Varesio, C.; Ferraro, O.E.; Tagliabue, A. Use of Remote Monitoring by E-mail for Long-Term Management of the Classic Ketogenic Diet. Nutrients 2020, 12, 1833. [Google Scholar] [CrossRef]
- Erkent, I.; Ilgaz, F.; Dericioglu, N. Difficulties in the implementation of the ketogenic diet in adult patients with refractory epilepsy. Epilepsy Behav. 2023, 144, 109234. [Google Scholar] [CrossRef]
- Armeno, M.; Verini, A.; Caballero, E.; Cresta, A.; Valenzuela, G.R.; Caraballo, R. Long-term effectiveness and adverse effects of ketogenic diet therapy in infants with drug-resistant epilepsy treated at a single center in Argentina. Epilepsy Res. 2021, 178, 106793. [Google Scholar] [CrossRef]
- Ye, F.; Li, X.-J.; Jiang, W.-L.; Sun, H.-B.; Liu, J. Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: A meta-analysis. J. Clin. Neurol. 2015, 11, 26–31. [Google Scholar] [CrossRef]
- Gutierrez-Colina, A.M.; Smith, A.W.; Mara, C.A.; Modi, A.C. Adherence barriers in pediatric epilepsy: From toddlers to young adults. Epilepsy Behav. 2018, 80, 229–234. [Google Scholar] [CrossRef]
- Chen, J.W.Y.; Wasterlain, C.G. Status epilepticus: Pathophysiology and management in adults. Lancet Neurol. 2006, 5, 246–256. [Google Scholar] [CrossRef] [PubMed]
- Davis, K.L.; Candrilli, S.D.; Edin, H.M. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008, 49, 446–454. [Google Scholar] [CrossRef] [PubMed]
- Modi, A.C.; Wu, Y.P.; Rausch, J.R.; Peugh, J.L.; Glauser, T.A. Antiepileptic drug nonadherence predicts pediatric epilepsy seizure outcomes. Neurology 2014, 83, 2085–2090. [Google Scholar] [CrossRef] [PubMed]
- Wu, Y.P.; Follansbee-Junger, K.; Rausch, J.; Modi, A. Parent and family stress factors predict health-related quality in pediatric patients with new-onset epilepsy. Epilepsia 2014, 55, 866–877. [Google Scholar] [CrossRef] [PubMed]
- DiIorio, C.; Shafer, P.O.; Letz, R.; Henry, T.R.; Schomer, D.L.; Yeager, K. Project EASE study group Project EASE: A study to test a psychosocial model of epilepsy medication managment. Epilepsy Behav. 2004, 5, 926–936. [Google Scholar] [CrossRef]
- Neri, L.D.C.L.; Sampaio, L.P.D.B. Validation of ketogenic diet adherence questionnaire: Keto-check. Arq Neuropsiquiatr 2022, 80, 794–801. [Google Scholar] [CrossRef]
- Revorêdo, L.D.S.; Maia, R.S.; Torres, G.D.V.; Chaves Maia, E.M. O uso da técnica delphi em saúde: Uma revisão integrativa de estudos brasileiros. RACS 2015, 22, 16. [Google Scholar] [CrossRef]
- Tsang, S.; Royse, C.F.; Terkawi, A.S. Guidelines for developing, translating, and validating a questionnaire in perioperative and pain medicine. Saudi J. Anaesth. 2017, 11, S80–S89. [Google Scholar] [CrossRef] [PubMed]
- Silvino, R.C.D.A.S.; Trida, V.C.; Castro, A.D.R.V.; Neri, L.D.C.L. Construction and validation of the neonatal nutritional risk screening tool. Rev. Paul. Pediatr. 2020, 39, e2020026. [Google Scholar] [CrossRef] [PubMed]
- Ferrando, P.J.; Lorenzo-Seva, U. Program FACTOR at 10: Origins, development and future directions. Psicothema 2017, 29, 236–240. [Google Scholar] [CrossRef] [PubMed]
- Lorenzo-Seva, U.; Ferrando, P.J. Factor Analysis; Universitat Rovira i Virgili: Tarragona, Spain, 2022. [Google Scholar]
- Lorenzo-Seva, U.; Ferrando, P.J. FACTOR: A computer program to fit the exploratory factor analysis model. Behav. Res. Methods 2006, 38, 88–91. [Google Scholar] [CrossRef] [PubMed]
- Lorenzo-Seva, U.; Van Ginkel, J.R. Multiple Imputation of missing values in exploratory factor analysis of multidimensional scales: Estimating latent trait scores. Analesps 2016, 32, 596. [Google Scholar] [CrossRef]
- Bartlett, M.S. A note on the multiplying factors for various chi square approximations. J. R. Stat. Soc. Ser. B 1954, 296–298. [Google Scholar]
- KAISER, H. An index of factorial simplicity. Psychometrika 1974, 39, 31–36. [Google Scholar] [CrossRef]
- Timmerman, M.E.; Lorenzo-Seva, U. Dimensionality assessment of ordered polytomous items with parallel analysis. Psychol. Methods 2011, 16, 209–220. [Google Scholar] [CrossRef] [PubMed]
- Ferrando, P.J.; Lorenzo-Seva, U. Assessing the quality and appropriateness of factor solutions and factor score estimates in exploratory item factor analysis. Educ. Psychol. Meas. 2018, 78, 762–780. [Google Scholar] [CrossRef] [PubMed]
- Browne, M.W.; Cudeck, R. Alternative ways of assessing model fit. In Testing Structural Equation Models; Bollen, K.A., Long, J.S., Eds.; Sage: Newcastle upon Tyne, UK, 1993; pp. 136–162. [Google Scholar]
- Cohen, J. Statistical Power Analysis for the Behavioral Sciences; 2nd ed.; Lawrence Erlbaum Associates, 1988.
- Tucker, L.; Lewis, C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika 1973, 38, 1–10. [Google Scholar] [CrossRef]
- Hu, L.; Bentler, P.M. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct. Equ. Model. A Multidiscip. J. 1999, 6, 1–55. [Google Scholar] [CrossRef]
- Jöreskog, K.G. LISREL: Analysis of linear structural relationships by maximum likelihood, instrumental variables, and least squares methods. . In Advances in Factor Analysis and Structural Equation Models; Jöreskog, K.G., Sörbom, D., Eds.; Abt Books, 1981; pp. 23–51.
- Lorenzo-Seva, U.; Ferrando, P.J. A simulation-based scaled test statistic for assessing model-data fit in least-squares unrestricted factor-analysis solutions.; Universitat Rovira i Virgili., 2022.
- Kinsman, S.L.; Vining, E.P.; Quaskey, S.A.; Mellits, D.; Freeman, J.M. Efficacy of the ketogenic diet for intractable seizure disorders: Review of 58 cases. Epilepsia 1992, 33, 1132–1136. [Google Scholar] [CrossRef] [PubMed]
- Hosain, S.A.; La Vega-Talbott, M.; Solomon, G.E. Ketogenic diet in pediatric epilepsy patients with gastrostomy feeding. Pediatr. Neurol. 2005, 32, 81–83. [Google Scholar] [CrossRef] [PubMed]
- Klein, P.; Janousek, J.; Barber, A.; Weissberger, R. Ketogenic diet treatment in adults with refractory epilepsy. Epilepsy Behav. 2010, 19, 575–579. [Google Scholar] [CrossRef] [PubMed]
- Kverneland, M.; Selmer, K.K.; Nakken, K.O.; Iversen, P.O.; Taubøll, E. A prospective study of the modified Atkins diet for adults with idiopathic generalized epilepsy. Epilepsy Behav. 2015, 53, 197–201. [Google Scholar] [CrossRef]
- Silvino, R.C.D.A.S.; Trida, V.C., Castro; Neri, L.D.C.L. The use of a formula-based ketogenic diet in children with refractory epilepsy. Arq Neuropsiquiatr 2017, 75, 234–237. [Google Scholar] [CrossRef]
- Cabrera, A.M.; Fain, H.; Fain, B.; Muniategui, J.; Buiras, V.M.; Galicchio, S.; Cacchia, P.A.; Retamero, M.; Ocampo, R.P.; Porto, M.B. Treatment of refractory epilepsy. A comparison between classic ketogenic diet and modified Atkins diet in terms of efficacy, adherence, and undesirable effects. Nutr. Hosp. 2021, 38, 1144–1148. [Google Scholar] [CrossRef]
- Santiworakul, C.; Chomtho, K.; Chomtho, S. Growth and nutritional status of pediatric patients treated with the ketogenic diet. Asia Pac. J. Clin. Nutr. 2021, 30, 231–237. [Google Scholar] [CrossRef] [PubMed]
- Green, S.F.; Nguyen, P.; Kaalund-Hansen, K.; Rajakulendran, S.; Murphy, E. Effectiveness, retention, and safety of modified ketogenic diet in adults with epilepsy at a tertiary-care centre in the UK. J. Neurol. 2020, 267, 1171–1178. [Google Scholar] [CrossRef] [PubMed]
- Mady, M.A.; Kossoff, E.H.; McGregor, A.L.; Wheless, J.W.; Pyzik, P.L.; Freeman, J.M. The ketogenic diet: Adolescents can do it, too. Epilepsia 2003, 44, 847–851. [Google Scholar] [CrossRef] [PubMed]
- Wibisono, C.; Rowe, N.; Beavis, E.; Kepreotes, H.; Mackie, F.E.; Lawson, J.A.; Cardamone, M. Ten-year single-center experience of the ketogenic diet: Factors influencing efficacy, tolerability, and compliance. J. Pediatr. 2015, 166, 1030–1036.e1. [Google Scholar] [CrossRef]
- McDonald, T.J.W.; Henry-Barron, B.J.; Felton, E.A.; Gutierrez, E.G.; Barnett, J.; Fisher, R.; Lwin, M.; Jan, A.; Vizthum, D.; Kossoff, E.H.; et al. Improving compliance in adults with epilepsy on a modified Atkins diet: A randomized trial. Seizure 2018, 60, 132–138. [Google Scholar] [CrossRef] [PubMed]
- Pasca, L.; Caraballo, R.H.; De Giorgis, V.; Reyes, J.G.; Macasaet, J.A.; Masnada, S.; Armeno, M.; Musicco, M.; Tagliabue, A.; Veggiotti, P. Ketogenic diet use in children with intractable epilepsy secondary to malformations of cortical development: A two- centre experience. Seizure 2018, 57, 34–37. [Google Scholar] [CrossRef] [PubMed]
- Baby, N.; Vinayan, K.P.; Pavithran, N.; Grace Roy, A. A pragmatic study on efficacy, tolerability and long term acceptance of ketogenic diet therapy in 74 South Indian children with pharmacoresistant epilepsy. Seizure 2018, 58, 41–46. [Google Scholar] [CrossRef] [PubMed]
- Bekker, Y.A.C.; Lambrechts, D.A.; Verhoeven, J.S.; van Boxtel, J.; Troost, C.; Kamsteeg, E.-J.; Willemsen, M.A.; Braakman, H.M.H. Failure of ketogenic diet therapy in GLUT1 deficiency syndrome. Eur. J. Paediatr. Neurol. 2019, 23, 404–409. [Google Scholar] [CrossRef]
- Kossoff, E.H.; Henry, B.J.; Cervenka, M.C. Efficacy of dietary therapy for juvenile myoclonic epilepsy. Epilepsy Behav. 2013, 26, 162–164. [Google Scholar] [CrossRef]
- Chomtho, K.; Suteerojntrakool, O.; Chomtho, S. Effectiveness of Medium Chain Triglyceride Ketogenic Diet in Thai Children with Intractable Epilepsy. J. Med. Assoc. Thai. 2016, 99, 159–165. [Google Scholar]
- Lee, H.-F.; Chi, C.-S.; Liao, J.-H. Use of cooking oils in a 2:1 ratio classical ketogenic diet for intractable pediatric epilepsy: Long-term effectiveness and tolerability. Epilepsy Res. 2018, 147, 75–79. [Google Scholar] [CrossRef] [PubMed]
- Alencastro Veiga Domingues Carneiro, R.; Dos Santos Lunardi, M.; Matheus Uberna Giacomini, F.; Kurrle Rieger, D.; Dubois Moreira, J.; Carina Ribeiro da Silva, L.; Pereira Brito Sampaio, L.; Lin, K. Challenges faced by people with epilepsy on ketogenic diet therapy and their caregivers during the COVID-19 pandemic in Brazil. Epilepsy Behav. 2021, 122, 108193. [Google Scholar] [CrossRef] [PubMed]
- Poorshiri, B.; Barzegar, M.; Tahmasebi, S.; Shiva, S.; Raeisi, S.; Ebadi, Z. The efficacy comparison of classic ketogenic diet and modified Atkins diet in children with refractory epilepsy: A clinical trial. Acta Neurol. Belg. 2021, 121, 483–487. [Google Scholar] [CrossRef] [PubMed]
- Michaelis, R.; Tang, V.; Wagner, J.L.; Modi, A.C.; LaFrance, W.C.; Goldstein, L.H.; Lundgren, T.; Reuber, M. Cochrane systematic review and meta-analysis of the impact of psychological treatments for people with epilepsy on health-related quality of life. Epilepsia 2018, 59, 315–332. [Google Scholar] [CrossRef]
- Operto, F.F.; Labate, A.; Aiello, S.; Perillo, C.; de Simone, V.; Rinaldi, R.; Coppola, G.; Pastorino, G.M.G. The Ketogenic Diet in Children with Epilepsy: A Focus on Parental Stress and Family Compliance. Nutrients 2023, 15, 58. [Google Scholar] [CrossRef]

| Characteristics | n (%) |
|---|---|
|
Gender Female Male |
10 (83.3) 2 (16.7) |
|
Italian Region of professional activity Lombardia Veneto Emilia Romagna Friuli Venezia Giulia Campania |
5 (41.7) 3 (25) 2 (16.7) 1 (8.3) 1 (8.3) |
|
Area of expertise Neurologist Dietitian Nutritionist (MD) |
7 (58.3) 3 (25) 2 (16.7) |
|
Professional practice area Assistance Teaching and Research Both |
2 (16.7) 0 (0) 10 (83.3) |
| Question | Relevance | Clarity | |||
|---|---|---|---|---|---|
| First round | Second round | First round | Second round | ||
| 1 | CVI | 0,92 | 1 | 0,83 | 1 |
| % Agreement | 83% | 100% | 67% | 100% | |
| 2 | CVI | 0,94 | 1 | 0,83 | 1 |
| % Agreement | 92% | 100% | 67% | 100% | |
| 3 | CVI | 0,92 | 1 | 0,83 | 1 |
| % Agreement | 83% | 100% | 67% | 100% | |
| 4 | CVI | 0,94 | 1 | 0,86 | 1 |
| % Agreement | 92% | 100% | 67% | 100% | |
| 5 | CVI | 0,94 | 1 | 0,78 | 0,97 |
| % Agreement | 92% | 100% | 50% | 92% | |
| 6 | CVI | 0,94 | 1 | 0,86 | 0,94 |
| % Agreement | 92% | 100% | 75% | 92% | |
| 7 | CVI | 0,97 | 1 | 0,92 | 0,97 |
| % Agreement | 92% | 100% | 83% | 92% | |
| 8 | CVI | 0,97 | 1 | 0,89 | 0,97 |
| % Agreement | 92% | 100% | 75% | 92% | |
| 9 | CVI | 1,00 | 1 | 0,86 | 1 |
| % Agreement | 100% | 100% | 67% | 100% | |
| 10 | CVI | 0,94 | 0,97 | 0,89 | 0,97 |
| % Agreement | 83% | 92% | 75% | 92% | |
| Final Score | First round | Second round | |||
| CVI | 0,94 | 0,97 | |||
| % Agreement | 83% | 92% | |||
| Characteristics | n (%) |
|---|---|
| Age (yrs) | |
| 0-2 | 9 (7,9) |
| 3-12 | 66 (57,9) |
| 13-20 | 29 (25,4) |
| >20 | 10 (8,8) |
| Total | 114 (100,0) |
| Diagnosis | |
| Glut 1 Syndrome | 64 (56,1) |
| Drug-resistant epilepsy | 35 (30,7) |
| Migraine | 1 (0,9) |
| Others | 14 (12,3) |
| Total | 114 (100,0) |
| Diet duration (months) | |
| <6 | 8 (7,3) |
| 6-12 | 16 (14,5) |
| 12-24 | 22 (20,0) |
| <24 | 64 (58,2) |
| Total | 110 (100,0) |
| Type of KDT | |
| cKDT | 93 (81,6) |
| MCT | 16 (14,0) |
| MAD | 4 (3,5) |
| LGIT | 1 (0,9) |
| Total | 114 (100,0) |
| Mean ketonemia referred by patients (mmol/dL) | |
| <2 | 29 (26,4) |
| 2-5 | 80 (72,7) |
| >5 | 1 (0,9) |
| Total | 110 (100,0) |
| Perceived efficacy on symptoms (%) | |
| 0-25 | 4 (3,5) |
| 25-50 | 13 (11,4) |
| 50-75 | 46 (40,4) |
| 75-100 | 51 (44,7) |
| Total | 114 (100,0) |
| Question | 1_a | 2_a | 3_a | 4_a | 5_a | 6_a | 7_a | 8_a | 9_a | 10_a | Score_1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1_b | 0,660* | ||||||||||
| 2_b | 0,655* | ||||||||||
| 3_b | 0,764* | ||||||||||
| 4_b | 0,708* | ||||||||||
| 5_b | 0,535* | ||||||||||
| 6_b | 0,486* | ||||||||||
| 7_b | 0,710* | ||||||||||
| 8_b | 0,738* | ||||||||||
| 9_b | 0,337* | ||||||||||
| 10_b | 0,736* | ||||||||||
| Score_2 | 0,849* |
| Question | Factor 1 | Factor 2 | Factor 3 |
|---|---|---|---|
| q1 | -0.080 | 0.997 | -0.050 |
| q2 | 0.087 | 0.692 | -0.045 |
| q3 | -0.207 | 0.293 | 0.659 |
| q4 | 0.336 | 0.321 | 0.103 |
| q5 | 1.044 | -0.062 | -0.078 |
| q6 | 0.033 | 0.010 | 0.356 |
| q7 | 0.341 | 0.506 | -0.075 |
| q8 | 0.078 | -0.058 | 0.993 |
| q9 | 0.388 | 0.164 | 0.194 |
| q10 | 0.122 | 0.041 | 0.419 |
| iKetocheck adherence’s categorization* | n | Mean | Standard deviation | 95% Confidence interval |
|---|---|---|---|---|
| Insufficient Good Excellent |
12 | 2,19 | 1,09 | (1,50-2,88) |
| 56 | 2,38 | 0,91 | (2,13-2,62) | |
| 45 | 2,64 | 1,16 | (2,29-2,99) | |
| Total | 114 | 2,46 | 1,04 | 2,27-2,65) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).